藥明康德(02359.HK):藥明基金一期擬斥2100萬美元認購D3 Bio的A-1系列股份
格隆匯 11 月 17日丨藥明康德(02359.HK)宣佈,於2020年11月17日,藥明基金一期等投資者與D3 Bio簽署購股協議,據此,藥明基金一期同意購買而D3 Bio同意發行及出售2100萬股A-1系列股份(佔D3 Bio第二次最終交割完成時全面攤薄及轉換後已發行股本約16.67%),總對價為2100萬美元。包括Hodge Lake、Bright Angel及藥明人民幣基金在內的合共七名其他投資者亦參與D3 Bio的A系列投資,且為購股協議的訂約方。
據悉,D3 Bio是一家全球性生物技術公司,專注於開發及商業化顛覆性精準藥物,以改善或替代未能或未能完全滿足大量患者需求的現有腫瘤學及免疫學標準護理療法。D3 Bio與各地的世界一流夥伴合作,通過開發至發現再到開發的漸進迭代循環,將醫療保健領域的深刻臨牀及市場見解與顛覆性的科技發展相結合。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.